Chronic lymphocytic leukemia (CLL) clinical features include symptoms seen at presentation, along with features seen due to lymphoid involvement, complications, and extramedullary manifestations.

Children averaged an annual growth velocity of 6.0 cm per year and an absolute height gain of 6.2 cm after 12 months of treatment. In children with achondroplasia in real-world settings, vosoritide ...

In the validation set, the model showed a sensitivity of 98%, specificity of 84%, and an accuracy of 90%. Multiparametric magnetic resonance imaging (MRI)-based machine learning techniques have the ...

Even after obtaining an accurate diagnosis, patients reported experiencing between 1 and 20 attacks per year. Patients with hereditary angioedema (HAE) from underrepresented racial and ethnic groups ...

Factors associated with poorer overall survival were older age, higher GIPSS score, TP53 mutations, and a cytopenic phenotype. Multiple prognostic scoring systems were validated in in an Asian cohort ...

Patients with aplastic anemia/PNH syndrome may need to be “transitioned” to treatment with eculizumab before bone marrow transplantation to reduce the risk for intravascular hemolysis and thrombosis.

The patients was treated with 15 mg/kg of ursodeoxycholic acid per day, which led to symptomatic improvements after 6 months. Researchers from Lebanon presented a rare case of occult primary ...

The panel discussions were grouped under 3 main areas that included the definition and clinical characteristics of the disease, diagnostic approaches, and current and future therapeutic avenues. A new ...

Huntington disease is most often characterized by a triad of motor, behavioral, and cognitive dysfunction, and here's how clinicians are managing it. Huntington disease (HD) is most often ...

TLK prevalence declined sharply between less than 1 year of age to less than 3, reinforcing the need for postural management during early motor development. Researchers in the Netherlands have ...

Research into how the health-related quality of life of patients with indolent systemic mastocytosis is affected is vital to disease management.

Between 2001 to 2011, annual age-adjusted incidence increased from 0.55/100,000 to 0.78/100,000, demonstrating an increasing trend with age. Incidence peaks in individuals over 70 years of age ...